The Shifting Landscape of AI & GenAI Adoption in Pharma

Artificial Intelligence (AI) and Generative AI (GenAI) are rapidly transitioning from isolated pilots to enterprise-wide initiatives across the pharmaceutical industry. While the opportunity to accelerate research, optimize clinical trials, and enhance decision-making is significant, scaling AI requires more than technology alone.

Success is increasingly defined by how well organizations align AI with strategy, governance, and measurable business outcomes. As pharma leaders move beyond experimentation, the focus shifts toward building sustainable, value-driven AI ecosystems supported by strong data foundations and operating models.

This white paper from EPAM explores how organizations can operationalize AI at scale—highlighting adoption models, governance challenges, and the balance between internal capabilities and external partnerships. It outlines practical pathways to help enterprises move from fragmented initiatives to mature, enterprise-wide AI adoption.

As AI continues to reshape the pharma landscape, the ability to govern data, ensure trust, and deliver measurable value will define long-term success.